Heart 2001;86:649-655 ( December )

Cardiovascular medicine

Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets C D Garlichs^a, S Eskafi^a, D Raaz^a, A Schmidt^a, J Ludwig^a, M Herrmann^b, L Klinghammer^a, W G Daniel^a, A Schmeisser^a

^a Medical Clinic II, Friedrich-Alexander University Erlangen-Nürnberg, Östliche Stadmauerstrasser 29, 91054 Erlangen, Germany, ^b Medical Clinic III, Friedrich-Alexander University Erlangen-Nürnberg

Correspondence to: Dr Garlichs christoph.garlichs{at}rzmail.uni-erlangen.de

Accepted 12 July 2001

OBJECTIVETo investigate whether CD40L/CD154 on platelets and soluble CD40L/CD154 may play a role in the inflammatory process of acute coronary syndromes.
DESIGN AND SETTINGObservational study in a university hospital.
PATIENTS15 patients with acute myocardial infarction, 25 patients with unstable angina, 15 patients with stable angina, and 12 controls.
MAIN OUTCOME MEASURESCD40L/CD154 on platelets, P-selectin/CD62P on platelets, soluble CD40L/CD154 serum concentrations.
RESULTSMean (SD) CD40L/CD154 expression on platelets was 6.2 (2.8) MFI (mean fluorescence intensity) in the infarct group, 11 (3.3) MFI in the unstable angina group (p < 0.001 v infarction), 3.6 (0.9) MFI in the stable angina group (p < 0.01 v infarction; p < 0.001 v unstable angina), and 3.2 (1.0) MFI in the controls (p < 0.01 v infarction; p < 0.001 v unstable angina; NS v stable angina). Soluble CD40L/CD154 concentration was 5.2 (1.1) ng/ml in the infarct group, 4.2 (0.7) ng/ml in the unstable angina group (p < 0.001 v infarction), 2.9 (1.0) ng/ml in stable angina group (p < 0.001 v infarction and unstable angina), and 3.0 (0.5) ng/ml in the controls (p < 0.001 v infarction and unstable angina; NS v stable angina). At a six months follow up, there was lower expression of CD40L/CD154 on platelets in patients with unstable angina (12.3 (3.6) v 3.8 (1.2) MFI, p < 0.0001) and acute myocardial infarction (6.2 (2.8) v 3.5 (0.8) MFI, p < 0.01) compared with their admission values six months earlier. Patients with unstable angina who needed redo coronary angioplasty (PTCA) or who had recurrence of angina were characterised by increased CD40L/CD154 expression on platelets compared with the remainder of the study group (recurrence of angina: 12.7 (3.2) v 9.7 (1.6) MFI, p < 0.05; re-do PTCA: 14.3 (4.2) v 10.3 (2.1) MFI, p < 0.05).
CONCLUSIONSBoth CD40L/CD154 on platelets and soluble CD40L/CD154 are raised in patients with unstable angina and myocardial infarction. These findings suggest that CD40-CD40L/CD154 interactions may play a pathogenic role in triggering and propagation of acute coronary syndromes.


Keywords: acute coronary syndromes; unstable angina; CD40L/CD154; platelets

---

© 2001 by Heart
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Antoniades, C., Bakogiannis, C., Tousoulis, D., Antonopoulos, A. S., Stefanadis, C. (2009). The CD40/CD40 ligand system: linking inflammation with atherothrombosis.. J Am Coll Cardiol 54: 669-677 [Abstract] [Full Text]  
• Kraaijeveld, A.O., de Jager, S.C.A., de Jager, W.J., Prakken, B.J., McColl, S.R., Haspels, I., Putter, H., van Berkel, T.J.C., Nagelkerken, L., Jukema, J.W., Biessen, E.A.L. (2007). CC Chemokine Ligand-5 (CCL5/RANTES) and CC Chemokine Ligand-18 (CCL18/PARC) Are Specific Markers of Refractory Unstable Angina Pectoris and Are Transiently Raised During Severe Ischemic Symptoms. Circulation 116: 1931-1941 [Abstract] [Full Text]  
• Steinhubl, S. R., Badimon, J. J., Bhatt, D. L., Herbert, J.-M., Luscher, T. F. (2007). Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 12: 113-122 [Abstract]  
• Chakrabarti, S., Varghese, S., Vitseva, O., Tanriverdi, K., Freedman, J. E. (2005). CD40 Ligand Influences Platelet Release of Reactive Oxygen Intermediates. Arterioscler. Thromb. Vasc. Bio. 25: 2428-2434 [Abstract] [Full Text]  
• Heeschen, C. (2005). Biomarkers in acute coronary syndromes and their role in diabetic patients. Diabetes and Vascular Disease Research 2: 122-127 [Abstract]  
• Ueland, T., Aukrust, P., Yndestad, A., Otterdal, K., Froland, S. S., Dickstein, K., Kjekshus, J., Gullestad, L., Damas, J. K. (2005). Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J 26: 1101-1107 [Abstract] [Full Text]  
• Apple, F. S., Wu, A. H.B., Mair, J., Ravkilde, J., Panteghini, M., Tate, J., Pagani, F., Christenson, R. H., Mockel, M., Danne, O., Jaffe, A. S., on behalf of the Committee on Standardization of M, (2005). Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. Clin. Chem. 51: 810-824 [Abstract] [Full Text]  
• Vishnevetsky, D., Kiyanista, V. A, Gandhi, P. J (2004). CD40 Ligand: A Novel Target in the Fight Against Cardiovascular Disease. The Annals of Pharmacotherapy 38: 1500-1508 [Abstract] [Full Text]  
• Kinlay, S., Schwartz, G. G., Olsson, A. G., Rifai, N., Sasiela, W. J., Szarek, M., Ganz, P., Libby, P., for the Myocardial Ischemia Reduction with Aggress, (2004). Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110: 386-391 [Abstract] [Full Text]  
• Mitsios, J. V., Papathanasiou, A. I., Rodis, F. I., Elisaf, M., Goudevenos, J. A., Tselepis, A. D. (2004). Atorvastatin Does Not Affect the Antiplatelet Potency of Clopidogrel When It Is Administered Concomitantly for 5 Weeks in Patients With Acute Coronary Syndromes. Circulation 109: 1335-1338 [Abstract] [Full Text]  
• Clatza, A., Bonifaz, L. C., Vignali, D. A. A., Moreno, J. (2003). CD40-Induced Aggregation of MHC Class II and CD80 on the Cell Surface Leads to an Early Enhancement in Antigen Presentation. J. Immunol. 171: 6478-6487 [Abstract] [Full Text]  
• Prasad, K. S. S., Andre, P., He, M., Bao, M., Manganello, J., Phillips, D. R. (2003). Soluble CD40 ligand induces {beta}3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc. Natl. Acad. Sci. USA 100: 12367-12371 [Abstract] [Full Text]  
• Danese, S, Katz, J A, Saibeni, S, Papa, A, Gasbarrini, A, Vecchi, M, Fiocchi, C (2003). Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 52: 1435-1441 [Abstract] [Full Text]  
• Stumpf, C., Lehner, C., Eskafi, S., Raaz, D., Yilmaz, A., Ropers, S., Schmeisser, A., Ludwig, J., Daniel, W. G., Garlichs, C. D. (2003). Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 5: 629-637 [Abstract] [Full Text]  
• Kennon, S, Price, C P, Mills, P G, Macey, M, Cooper, J, Clarke, H, Timmis, A D (2003). The central role of platelet activation in determining the severity of acute coronary syndromes. Heart 89: 1253-1254 [Full Text]  
• Garlichs, C.D., Kozina, S., Fateh-Moghadam, S., Tomandl, B., Stumpf, C., Eskafi, S., Raaz, D., Schmeisser, A., Yilmaz, A., Ludwig, J., Neundorfer, B., Daniel, W.G. (2003). Upregulation of CD40-CD40 Ligand (CD154) in Patients With Acute Cerebral Ischemia. Stroke 34: 1412-1418 [Abstract] [Full Text]  
• Inwald, D. P., McDowall, A., Peters, M. J., Callard, R. E., Klein, N. J. (2003). CD40 Is Constitutively Expressed on Platelets and Provides a Novel Mechanism for Platelet Activation. Circ. Res. 92: 1041-1048 [Abstract] [Full Text]  
• Nannizzi-Alaimo, L., Alves, V. L., Phillips, D. R. (2003). Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation. Circulation 107: 1123-1128 [Abstract] [Full Text]  
• Wang, C.-L., Wu, Y.-T., Liu, C.-A., Lin, M.-W., Lee, C.-J., Huang, L.-T., Yang, K. D. (2003). Expression of CD40 Ligand on CD4+ T-Cells and Platelets Correlated to the Coronary Artery Lesion and Disease Progress in Kawasaki Disease. Pediatrics 111: e140-147 [Abstract] [Full Text]  
• Semb, A. G., van Wissen, S., Ueland, T., Smilde, T., Waehre, T., Tripp, M. D., Froland, S. S., Kastelein, J. J. P., Gullestad, L., Pedersen, T. R., Aukrust, P.a., Stalenhoef, A. F. H. (2003). Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 41: 275-279 [Abstract] [Full Text]  
• Andre, P., Nannizzi-Alaimo, L., Prasad, S. K., Phillips, D. R. (2002). Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease. Circulation 106: 896-899 [Full Text]  
• Nannizzi-Alaimo, L., Rubenstein, M. H., Alves, V. L., Leong, G. Y., Phillips, D. R., Gold, H. K. (2002). Cardiopulmonary Bypass Induces Release of Soluble CD40 Ligand. Circulation 105: 2849-2854 [Abstract] [Full Text]  
• AUKRUST, P., WAeHRE, T., DAMAS, J. K., GULLESTAD, L., SOLUM, N. O. (2001). Inflammatory role of platelets in acute coronary syndromes. Heart 86: 605-606 [Full Text]